Company

Revelyx Bio Inc.

Revelyx Bio develops liquid botulinum toxin products for cosmetic and medical applications.

About

Revelyx Bio develops liquid botulinum toxin products for aesthetic and medical use. Its pipeline includes a botulinum toxin type A formulation designed for precision and usability. Founded in 2025 and based in Ohio, US, the company raised Series A funding in January 2026, led by NRL Capital.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in